KeyBanc lowered the firm’s price target on Alcon (ALC) to $105 from $107 and keeps an Overweight rating on the shares. The firm remains confident in a mid to high single digit trajectory into Q4 2024 and 2025, supported by sustained market growth trends and company-specific drivers. KeyBanc believes its end markets are amongst the most resilient in MedTech and include multiple ongoing trade-ups driving healthy industry growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
Questions or Comments about the article? Write to editor@tipranks.com